Division of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Yuan Ming Yuan West Road No. 2, Haidian District, 100193, People's Republic of China.
Division of Veterinary Pathology, College of Veterinary Medicine, China Agricultural University, Yuan Ming Yuan West Road No. 2, Haidian District, 100193, People's Republic of China.
J Ethnopharmacol. 2020 Sep 15;259:112944. doi: 10.1016/j.jep.2020.112944. Epub 2020 May 5.
Huai hua san (HHS) is a traditional Chinese herbal formula which is firstly documented in the ancient Chinese classic medical work "Pu Ji Ben Shi Fang" in 1132 AD. It has been widely used in the treatment of lower gastrointestinal disorders such as acute colitis and hematochezia for more than 800 years. However, scientific evidence of the efficacy and the exact mechanism of HHS against colitis has not yet been reported.
The aim of this study is to investigate the potential effects of HHS in the alleviation of dextran sulphate sodium (DSS)-induced colitis and the alteration of colonic microbiota composition and structure.
HHS solution was orally administrated to 5% DSS-challenged rats once a day for 8 days. Colitis clinical symptoms of colitis were collected, together with colonic mucosal damage assessed at histomorphometric and ultrastructural levels. The protein levels of inflammatory mediators TNF-α and CRP were detected by ELISA. The colonic vascular permeability was evaluated by Evans blue extravasation. Meanwhile, The effects of the HHS therapy on the colonic microbiota were evaluated by analyzing the V3 and V4 regions of the 16S rRNA gene by Illumina sequencing and multivariate statistical methods.
Daily oral administration of HHS markedly alleviated DSS-induced colitis, as evidenced by decreased colitis disease activity index (DAI) score, reduced colonic inflammation and normalization of colonic vascular hyperpermeability. Moreover, the 16S rRNA gene sequencing analysis demonstrated that HHS treatment during colitis prevented the colitis-associated alteration of colonic microbial community at operational taxonomic unit level, together with the DSS-induced colonic microbiota dysbiosis at taxonomic levels. In addition, HHS therapy reduced colitis-associated high increased ratio of Bacteroidetes to Firmicutes to a normal level.
HHS could attenuate ulcerative colitis and ameliorate gut microbial dysbiosis.
槐黄散（HHS）是一种中药复方，最早记录于公元 1132 年的古代中医经典著作《普济本事方》中。它已被广泛用于治疗下胃肠道疾病，如急性结肠炎和便血，已有 800 多年的历史。然而，槐黄散治疗结肠炎的疗效和确切机制的科学证据尚未报道。
本研究旨在探讨槐黄散对葡聚糖硫酸钠（DSS）诱导的结肠炎的缓解作用，以及对结肠微生物群落组成和结构的改变。
槐黄散溶液每天口服一次，5%DSS 挑战大鼠 8 天。收集结肠炎临床症状，同时通过组织形态计量学和超微结构水平评估结肠黏膜损伤。通过 ELISA 检测炎症介质 TNF-α和 CRP 的蛋白水平。通过 Evans 蓝渗出评估结肠血管通透性。同时，通过 Illumina 测序和多变量统计方法分析 16S rRNA 基因的 V3 和 V4 区，评估槐黄散治疗对结肠微生物群的影响。
槐黄散的每日口服显著缓解 DSS 诱导的结肠炎，表现在疾病活动指数（DAI）评分降低、结肠炎症减轻和结肠血管高通透性正常化。此外，16S rRNA 基因测序分析表明，槐黄散治疗在结肠炎期间防止了结肠炎相关的结肠微生物群落在操作分类单元水平上的改变，以及 DSS 诱导的结肠微生物群失调在分类水平上。此外，槐黄散治疗降低了结肠炎相关的厚壁菌门到拟杆菌门的比例升高，使其恢复到正常水平。
槐黄散可减轻溃疡性结肠炎并改善肠道微生物失调。
